Volume 16, Number 7—July 2010
Dispatch
Postexposure Treatment of Marburg Virus Infection
Table 1
Animal no. | Group | Treatment | Time of treatment after challenge, h | Plasma† |
PBMC |
|||||
---|---|---|---|---|---|---|---|---|---|---|
Day 6 | Day 10 | Day 14 | Day 6 | Day 10 | Day 14 | |||||
1 | Exp 1 | VSV-Marburg | 24 | 0 (–) | 0 (–) | 0 (–) | NT (–) | NT (+) | NT | |
2 | Exp 1 | VSV-Marburg | 24 | 0 (–) | 0 (–) | 0 (–) | NT (–) | NT (+) | NT (–) | |
3 | Exp 1 | VSV-Marburg | 24 | 3.76 (–) | 6.19 (+) | NT (–) | NT (+) | |||
4 | Exp 1 | VSV-Marburg | 24 | 0 (–) | 0 (–) | 0 (–) | NT (–) | NT (–) | NT (–) | |
5 | Exp 1 | VSV-Marburg | 24 | 0 (–) | 0 (–) | 0 (–) | NT (–) | NT (–) | NT (–) | |
6 | Exp 1 | VSV-Marburg | 24 | 0 (–) | 0 (–) | 0 (–) | NT (–) | NT (–) | NT (–) | |
Control 1 | Cont 1 | VSV-Lassa | 24 | 3.76 (–) | 7.33 (+) | NT (–) | NT (+) | |||
7 | Exp 2 | VSV-Marburg | 48 | 0 (–) | 4.20 (+) | 0 (–) | NT (+) | NT (+) | NT (–) | |
8 | Exp 2 | VSV-Marburg | 48 | 0 (–) | 7.27 (+) | NT (+) | NT (+) | |||
9 | Exp 2 | VSV-Marburg | 48 | 3.76 (–) | 7.25 (+) | NT (+) | NT (+) | |||
10 | Exp 2 | VSV-Marburg | 48 | 0 (–) | 0 (–) | 0 (–) | NT (–) | NT (–) | NT (–) | |
11 | Exp 2 | VSV-Marburg | 48 | 5.24 (+) | 7.35 (+) | NT (+) | NT (+) | |||
12 | Exp 2 | VSV-Marburg | 48 | 3.76 (–) | 6.81 (+) | NT (–) | NT (+) | |||
Control 2 | Cont 2 | VSV-Lassa | 48 | 4.05 (–) | 7.24 (+) | NT (+) | NT (+) | |||
Control 3 | Cont 3 | None | NA | 5.07 (+) | 7.15 (+) | NT (+) | NT (+) |
*PBMC, peripheral blood mononuclear cells; Exp, experimental; VSV, vesicular stomatitis virus; NT, not tested; Cont, control; (+), sample positive for Marburg virus by reverse transcription–PCR (RT-PCR); (−), sample negative for Marburg virus by RT-PCR; NA, not applicable.
†Log10 PFU of Marburg virus per milliliter of plasma.
Page created: March 02, 2011
Page updated: March 02, 2011
Page reviewed: March 02, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.